Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sits in the top decile of US sponsors by registered trial count (#204 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University: 138 sponsored US clinical trials, 4 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sponsors 138 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 101 completed. 4 of these trials are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreatic Cancer, with 2 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University ranks in the top decile of sponsors by registered trial count (#204 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
101 of 129 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
138 total, page 1 of 3
Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study
NCT07501663
Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry
NCT06974981
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
NCT03184038
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02757859
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
NCT03796884
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
NCT03198026
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
NCT03251027
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
NCT02068586
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
NCT01655836
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
NCT03712904
Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR)
NCT03807492
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
NCT03618654
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
NCT03712878
Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy
NCT03580499
Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer
NCT03578224
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT03472573
Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma
NCT03477110
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
NCT03472586
Remote Activity Monitored by Fitbit Charge 3 in Investigating Daily Step and Sleep Data in Participants With Head and Neck Cancer Undergoing Radiation Therapy
NCT03489252
Automated Device for Asthma Monitoring and Management in Monitoring Adults With Lung Cancer Undergoing Radiation Therapy
NCT03340714
Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis
NCT03318380
Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
NCT03405155
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
NCT03366766
Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
NCT03342911
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
NCT03317899
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
NCT03076203
SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary Pancreatic Cancer With Severe Obstructive Jaundice
NCT03820544
Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT03238365
Decision Counseling Program in Increasing Shared Decision Making and Clinical Trial Participation in Patients With Stage 0-IV Lung Cancer (Free to Breathe)
NCT03820557
Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery
NCT03297112
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
NCT03162731
Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma
NCT03076281
Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation
NCT02899221
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy
NCT03063944
Using a Head and Neck Maskless Immobilization Device For Patients With Intracranial Tumors
NCT03076255
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
NCT03032783
Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
NCT03109873
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
NCT03109847
Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)
NCT02555176
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
NCT02896907
Educational Intervention in Increasing Knowledge About Prostate Cancer in High-Risk Neighborhoods
NCT03197896
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
NCT03039413
Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer
NCT02983279
Electronic Patient Reported Outcomes in Measuring Health-Related Quality of Life in Patients With Stage I-IV Prostate Cancer Undergoing Treatment
NCT03197948
CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer
NCT02827370
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
NCT02874430
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
NCT02764801
Telehealth in Improving Quality of Life in Patients During Post Radiation Therapy Visits
NCT02751580
Contrast Ultrasound Detection of Sentinel Lymph Nodes
NCT02652923
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
NCT02555189
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 41 |
| Phase 3 | 4 |
What is open in the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University pipeline
4 recruiting of 138 indexed (3% open); 101 completed (73%).
Phase mix: 4 late (III/IV) vs 93 early (I/II) (early-phase heavy).
Top condition: Pancreatic Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University: open-pipeline peers nationwide
Peers matched on 138 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 138 trials (± recruiting share)
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Barbara Ann Karmanos Cancer Institute · 139 trials · 12% recruiting
- Centers for Disease Control and Prevention · 139 trials · 2% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Merz North America · 3% recruiting · 35 trials
- VIVUS · 3% recruiting · 35 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University page
138 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University or any single study.
- 4 of Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pancreatic Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreatic Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University pipeline card: 138 registered trials from official public datasets.Report a data error.